

APRETUDE (CABOTEGRAVIR)



4 Years
FORWARD*

*Received FDA approval in 2021.

Compensated by ViiV Healthcare.

Please see Important Safety Information throughout and full [Prescribing Information](#), including Boxed Warning, for APRETUDE.

“

My provider is

MY BEST ALLYto empower me to be proactive
in my health—and good
communication creates**A SAFE SPACE**to share and discuss
my needs.”

- Ruben

Celebrating
4 years
of *innovation*
& *impact*Pearl Pugh
SVP & Head, ViiV US

At ViiV Healthcare, we are dedicated to putting patients first. As the only pharmaceutical company solely focused on HIV, our mission guides our work. We believe that every person living with or impacted by HIV deserves care, support, and for their voices to be heard.

ViiV received FDA approval at the end of 2021 for APRETUDE, the first ever long-acting injectable for HIV prevention. This innovation was driven by the needs of communities and meant that—for the first time ever—there would be a long-acting injectable (LAI) option for PrEP.

Amplifying the voices of people and communities impacted by HIV is central to our work. We hope that by sharing stories of these APRETUDE ambassadors, we'll help elevate their journeys and inspiration within the community.

On behalf of ViiV Healthcare, I'm honored to share this special magazine edition celebrating our fourth anniversary, featuring stories from four outstanding individuals who recount their experiences with APRETUDE.

INDICATION

APRETUDE is indicated for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in adults and adolescents weighing at least 35 kg who are at risk for HIV-1 acquisition. Individuals must have a negative HIV-1 test prior to initiating APRETUDE (with or without an oral lead-in with oral cabotegravir) for HIV-1 PrEP.

IMPORTANT SAFETY INFORMATION

BOXED WARNING: RISK OF DRUG RESISTANCE WITH USE OF APRETUDE FOR HIV-1 PRE-EXPOSURE PROPHYLAXIS (PrEP) IN UNDIAGNOSED HIV-1 INFECTION

Individuals must be tested for HIV-1 infection prior to initiating APRETUDE or oral cabotegravir, and with each subsequent injection of APRETUDE, using a test approved or cleared by the FDA for the diagnosis of acute or primary HIV-1 infection. Drug-resistant HIV-1 variants have been identified with use of APRETUDE by individuals with undiagnosed HIV-1 infection.

Do not initiate APRETUDE for HIV-1 PrEP unless negative infection status is confirmed. Individuals who acquire HIV-1 while receiving APRETUDE for PrEP must transition to a complete HIV-1 treatment regimen.


CONTRAINDICATIONS

- Do not use APRETUDE in individuals:
 - with unknown or positive HIV-1 status
 - with previous hypersensitivity reaction to cabotegravir
 - receiving carbamazepine, oxcarbazepine, phenobarbital, phenytoin, rifampin, and rifapentine

Please see additional Important Safety Information continued throughout and full [Prescribing Information](#), including Boxed Warning, for APRETUDE (cabotegravir).



TIMELINE



IMPORTANT SAFETY INFORMATION (CONT'D)

WARNINGS AND PRECAUTIONS

Comprehensive Management to Reduce the Risk of HIV-1 Infection:

- Use APRETUDE as part of a comprehensive prevention strategy, including adherence to the administration schedule and safer sex practices, including condoms, to reduce the risk of sexually transmitted infections (STIs). APRETUDE is not always effective in preventing HIV-1 acquisition. Risk for HIV-1 acquisition includes, but is not limited to, condomless sex, past or current STIs, self-identified HIV risk, having sexual partners of unknown HIV-1 viremic status, or sexual activity in a high prevalence area or network. Inform, counsel, and support individuals on the use of other prevention measures (e.g., consistent and correct condom use; knowledge of partner[s] HIV-1 status, including viral suppression status; regular testing for STIs)
- Use APRETUDE only in individuals confirmed to be HIV-1 negative. HIV-1 resistance substitutions may emerge in individuals with undiagnosed HIV-1 infection who are taking only APRETUDE, because APRETUDE alone does not constitute a complete regimen for HIV-1 treatment. Prior to initiating APRETUDE, ask seronegative individuals about recent (in past month) potential exposure events and evaluate for current or recent signs or symptoms consistent with acute HIV-1 infection (e.g., fever, fatigue, myalgia, skin rash). If recent (<1 month) exposures to HIV-1 are suspected or clinical symptoms consistent with acute HIV-1 infection are present, use a test approved or cleared by the FDA as an aid in the diagnosis of acute HIV-1 infection

Please see additional Important Safety Information continued throughout and full [Prescribing Information](#), including Boxed Warning, for APRETUDE (cabotegravir).

CLINICAL EVIDENCE *from*
HPTN 083 and HPTN 084, *along with*
REAL-WORLD EXPERIENCE

>27,000
patients

on APRETUDE (cabotegravir)*

>340,000
doses administered

in the US*

*Based on data from IQVIA: NCP, NSP, DDD (9/30/2025). IQVIA reserves all rights to this data.

AIDS=acquired immunodeficiency syndrome; AZT=azidothymidine; DDD=drug distribution data; HPTN=HIV Prevention Trials Network; NCP=national custom patient; NSP=national sales perspective.

IMPORTANT SAFETY INFORMATION (CONT'D)

WARNINGS AND PRECAUTIONS (CONT'D)

Comprehensive Management to Reduce the Risk of HIV-1 Infection: (cont'd)

- When using APRETUDE, HIV-1 testing should be repeated prior to each injection and upon diagnosis of any other STIs
- Additional HIV testing to determine HIV status is needed if an HIV-1 test indicates possible HIV-1 infection or if symptoms consistent with acute HIV-1 infection develop following an exposure event. If HIV-1 infection is confirmed, then transition the individual to a complete HIV-1 treatment
- Counsel individuals without HIV-1 to strictly adhere to the recommended dosing and testing schedule for APRETUDE

Potential Risk of Resistance with APRETUDE:

- There is a potential risk of developing resistance to APRETUDE if an individual acquires HIV-1 either before, while taking, or following discontinuation of APRETUDE. To minimize this risk, it is essential to clinically reassess individuals for risk of HIV-1 acquisition and to test before each injection to confirm HIV-1–negative status. Individuals who are confirmed to have HIV-1 infection must transition to a complete HIV-1 treatment. If individuals at continuing risk of HIV-1 acquisition discontinue APRETUDE, alternative forms of PrEP should be considered and initiated within 2 months of the final injection of APRETUDE

HPTN 083 *and* HPTN 084 STUDY INFORMATION

The clinical trials for APRETUDE, HPTN 083 (N=4566 cisgender men and transgender women who have sex with men) and HPTN 084 (N=3224 cisgender women), were randomized, double-blind, controlled trials evaluating the safety and efficacy of APRETUDE every 2 months[†] vs daily oral TRUVADA for HIV-1 prevention in adults at risk of sexually acquiring HIV-1. The primary endpoint of both studies was the rate of incident HIV-1 infections.

HPTN 083 incident HIV-1 infections: TRUVADA: 39 in 3193 person-years (1.22/100 person-years) and APRETUDE: 12 in 3211 person-years (0.37/100 person-years), HR 0.31 (95% CI: 0.16-0.58); P=0.0003.

HPTN 084 incident HIV-1 infections: TRUVADA: 36 in 1946 person-years (1.85/100 person-years) and APRETUDE: 3 in 1960 person-years (0.15/100 person-years), HR 0.10 (95% CI: 0.04-0.27); P<0.0001.

The most common adverse reactions (all grades) observed in ≥5% of participants receiving APRETUDE were injection site reactions[‡] (HPTN 083: 82%; HPTN 084: 38%), headache (HPTN 083: 4%; HPTN 084: 12%).



IMPORTANT SAFETY INFORMATION (CONT'D)

WARNINGS AND PRECAUTIONS (CONT'D)

Long-Acting Properties and Potential Associated Risks with APRETUDE:

- Residual concentrations of cabotegravir may remain in the systemic circulation of individuals for prolonged periods (up to 12 months or longer). Take the prolonged-release characteristics of cabotegravir into consideration and carefully select individuals who agree to the required every-2-month injection dosing schedule because non-adherence or missed doses could lead to HIV-1 acquisition and development of resistance

Please see additional Important Safety Information continued throughout and full [Prescribing Information](#), including [Boxed Warning](#), for APRETUDE.

[†]APRETUDE is administered as an intramuscular injection by a healthcare professional every 2 months after 2 initiation injections administered 1 month apart.

[‡]Participants who received injection: HPTN 083, APRETUDE (n=2117) and TRUVADA (n=2081); HPTN 084, APRETUDE (n=1519), and TRUVADA (n=1516).

BEYOND

THE DATA

REAL-LIFE EXPERIENCE MATTERS



Meet Leo, Shae, Zach, and Ruben.

We sat down with four individuals who take APRETUDE (cabotegravir) to get their perspectives. Learn about their journeys and their relationships with healthcare providers, with loved ones, and with themselves.

Please see additional Important Safety Information continued throughout and full Prescribing Information, including Boxed Warning, for APRETUDE.



GETTING *PrEP* THAT I KNEW I NEEDED

ZACH

Zach's story starts with his twin brother, who was diagnosed with HIV in 2008. Learning to love and care for himself was the key to taking the next step toward protection and talking to his doctor about HIV prevention.

Hello, Zach! First, thank you for sitting down for this conversation today. Let's start by hearing a little bit about you. In a few words, how would you describe yourself? What's important to you?

Thank you for having me. I'm so excited for this discussion. I have a story to tell and I know if it reaches the right people, it can make a difference. I am an exciting, unpredictable person with a lot of empathy. Relationships are important to me. I love spending time with my family and I'm super close with my twin brother, Greg (whom I affectionately

call Greggie). And I'm a huge fan of comics and cartoons. I get invested in the stories and follow all the different shows and movies with my favorite characters.

What motivated you to pursue PrEP to help prevent HIV?

What motivated me was realizing that no one is going to take care of me the way I take care of myself. Another big motivator for me is my twin brother. When I told him I had the opportunity to be a part of a long-acting PrEP study, Greg encouraged me just to do it. He said, "Do it." PrEP wasn't available to Greggie, but he is glad it's out there now. The love and respect I have for my brother, even when I was still learning to love and respect myself, made me listen to him and talk to my doctor and do it.



IMPORTANT SAFETY INFORMATION (CONT'D)

WARNINGS AND PRECAUTIONS (CONT'D)

Hypersensitivity Reactions:

- Serious or severe hypersensitivity reactions have been reported with APRETUDE, including Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN)
- Discontinue APRETUDE immediately if signs or symptoms of hypersensitivity reactions develop. Clinical status, including liver transaminases, should be monitored and appropriate therapy initiated

Hepatotoxicity:

- Hepatotoxicity has been reported in a limited number of individuals receiving cabotegravir with or without known pre-existing hepatic disease or identifiable risk factors

- Clinical and laboratory monitoring should be considered and APRETUDE should be discontinued if hepatotoxicity is suspected and individuals managed as clinically indicated

Depressive Disorders:

- Depressive disorders (including depression, depressed mood, major depression, persistent depressive disorder, suicidal ideation or attempt) have been reported with APRETUDE
- Promptly evaluate patients with depressive symptoms

Please see additional Important Safety Information continued throughout and full [Prescribing Information](#), including Boxed Warning, for APRETUDE (cabotegravir).



Zach and his brother, Greg, at age 6 (photographer unknown).

One reason we're here today is to talk about APRETUDE. How did you move from talking to your brother to having that conversation with your doctor?

I eventually had to leave the APRETUDE study because I moved back to Texas, where I'm from, in 2019. But right after APRETUDE was approved in December 2021, I called my primary care physician in January 2022 and worked with his assistant to set up an appointment. The assistant called me a few days later to set up the preauthorization process for me, and I was so freaking excited to find that my insurance approved me for APRETUDE. I told my brother and my partner; it felt like I had won a gold medal.

You spoke earlier about how important relationships are to you. Did your experience with APRETUDE impact your communication with your healthcare provider?

When I was still involved in the clinical trial for APRETUDE, I started to think about finding a provider who would be affirming of my identity and prepared to address my needs when it came to sexual health. I found a primary care doctor who fit that description and have been seeing him for years. Working with a provider who understands and accepts me has had a huge impact on my overall approach to my health. And I've had more and more opportunities to build trust and form a relationship with my doctor with each APRETUDE appointment.

Your story with APRETUDE goes back several years. With several PrEP options available, why do you continue taking APRETUDE?

I've chosen to stay with APRETUDE because it fits really well into my schedule and I'm comfortable with it. APRETUDE's every-two-month schedule (after 2 initiation doses 1 month apart) works perfectly for me. It's not just about getting the injection—it's also a chance to stay updated on any tests, review results, and stay informed about my health status. Even before starting APRETUDE, I was already going in for rapid HIV testing every two months. That cadence feels right to me. Regular check-ins with my provider help me feel proactive and stay informed.

We've talked about the past and the present with respect to your HIV prevention journey. Can you share your vision for the future of HIV prevention?

I want everyone to be able to find the love for themselves that motivated me to get on APRETUDE. My brother and his experience helped me take the next step forward in caring for myself by getting protected from HIV as part of a holistic approach. I know not everyone will have someone like that in their lives to inspire them, but I hope everyone can see that they're worthy of loving and taking care of themselves.



Zach and Greg today (photo credit: Travon C. Printis).

IMPORTANT SAFETY INFORMATION (CONT'D)

WARNINGS AND PRECAUTIONS (CONT'D)

Risk of Reduced Drug Concentration of APRETUDE Due to Drug Interactions:

- The concomitant use of APRETUDE and other drugs may result in reduced drug concentration of APRETUDE
- Refer to the full Prescribing Information for steps to prevent or manage these possible and known significant drug interactions, including dosing recommendations. Consider the potential for drug interactions prior to and during use of, and after discontinuation of APRETUDE; review concomitant medications during use of APRETUDE

ADVERSE REACTIONS

The most common adverse reactions (incidence $\geq 1\%$, all grades) with APRETUDE were injection site reactions, diarrhea, headache, pyrexia, fatigue, sleep disorders, nausea, dizziness, flatulence, abdominal pain,

vomiting, myalgia, rash, decreased appetite, somnolence, back pain, and upper respiratory tract infection.

DRUG INTERACTIONS

- Refer to the full Prescribing Information for important drug interactions with APRETUDE
- Drugs that induce UGT1A1 may significantly decrease the plasma concentrations of cabotegravir

USE IN SPECIFIC POPULATIONS

- **Lactation:** Assess the benefit-risk of using APRETUDE to the infant while breastfeeding due to the potential for adverse reactions and residual concentrations in the systemic circulation for up to 12 months or longer after discontinuation
- **Pediatrics:** Not recommended in individuals weighing less than 35 kg



SHAE

ADVOCATING for MY PROTECTION

Shae has a love life worth talking about. She helps people find connection by sharing her experiences with sexuality and sexual health as a Black, cisgender woman on APRETUDE.

Welcome, Shae. Thank you for being here. Can you tell us about yourself?

I'm glad to be here. I am a matchmaker and dating coach. I'm an entrepreneur and a boss babe with lots going on, both in my personal and professional life! I love to be bold, be myself, and help others. In my work, as someone who encourages people to date, sex is an important topic—and I think it's part of my job to empower people to be proactive about their sexual health. Everyone needs to be realistic about what they do and don't know about their partners, including HIV status, and that can lead people to recognize that PrEP is an option.

It makes sense that PrEP conversations come up in your work. You're also here because you've been taking APRETUDE since 2023. What motivated you to pursue PrEP to help prevent HIV?

I am sexually active and sex-positive, which means I promote open, tolerant, and progressive attitudes toward sex and sexuality. I'm even working on a writing project documenting some of my most exciting, romantic experiences. My work helps me recognize that, as a Black, cisgender woman who is sexually active, I need to protect myself from HIV, and I know APRETUDE is one part of an overall approach to HIV prevention. You don't know what you don't know about your partners, from their history to their current behavior. That means I recognize the importance of doing what I can: communicating with my partners, going in regularly for STI and HIV testing, and for me, talking to my doctor about PrEP.

When you talked to your doctor, what happened next?

When I initially started on PrEP, once I called my doctor to express my interest, I knew I was ready to move forward. I wanted the injection from the beginning because I didn't want to add a daily pill to my routine. At the time, there was only one injectable form of PrEP.

I started APRETUDE, and I've continued it because the every-2-month dosing (after 2 initiation doses) works well for me and my lifestyle. My provider also explained that it was important for me to practice safer sex.* They were excited that I was ready to try PrEP as a straight cis Black woman, and I was the first at their office. Before my initial injection, there were baseline tests performed to check my overall health and to confirm my negative HIV status.

With several PrEP options available, why do you continue taking APRETUDE?

I've been on APRETUDE for over 2 years, and what makes me feel secure in my decision to be on APRETUDE is the regular HIV testing I receive from my doctor every two months. Because I also ask for STI testing, knowing my HIV and STI status helps me feel assured. I'm committed to responsible pleasure. I'm proactive about my health, and I like that APRETUDE makes me pause and check in with myself and my providers regularly. My whole routine helps me feel in control of my sexual health.

The location and method of injection works well for me. When I go to my APRETUDE appointments, it's administered into the muscle of my butt, which is a private area. I've been able to go about the rest of my day after my appointment. Also, I take certain medications and supplements. I keep a list of them, and I show it to my doctor, especially before I start something new. This way I can talk to my doctor to be sure that APRETUDE does not interact with anything I'm currently taking or plan to take. As long as my doctor and I agree it's appropriate, I can foresee keeping APRETUDE as part of my HIV prevention plan for some time.

It's exciting that you can see APRETUDE as part of your plan going forward. Looking to the future, what is one of your hopes for HIV prevention?

I would like to see more recognition of the fact that anyone who is sexually active may have exposure to HIV and might consider PrEP. I want to see more people that are appropriate for PrEP actually on it and considering options like APRETUDE to help protect themselves from HIV. I want everyone to be able to be like me: living and loving out loud authentically—and knowing they're taking steps to help protect themselves from HIV as part of a comprehensive approach.

*APRETUDE is not always effective in preventing HIV-1 acquisition. Counsel individuals on an overall prevention strategy, including adherence to the administration schedule, knowledge of partner status, testing for STIs, and condom use. Inform individuals about and support their efforts in reducing sexual risk behavior.

IMPORTANT SAFETY INFORMATION

BOXED WARNING: RISK OF DRUG RESISTANCE WITH USE OF APRETUDE FOR HIV-1 PRE-EXPOSURE PROPHYLAXIS (PrEP) IN UNDIAGNOSED HIV-1 INFECTION

Individuals must be tested for HIV-1 infection prior to initiating APRETUDE or oral cabotegravir, and with each subsequent injection of APRETUDE, using a test approved or cleared by the FDA for the diagnosis of acute or primary HIV-1 infection. Drug-resistant HIV-1 variants have been identified with use of APRETUDE by individuals with undiagnosed HIV-1 infection.

Do not initiate APRETUDE for HIV-1 PrEP unless negative infection status is confirmed. Individuals who acquire HIV-1 while receiving APRETUDE for PrEP must transition to a complete HIV-1 treatment regimen.

CONTRAINDICATIONS

- Do not use APRETUDE in individuals:
 - with unknown or positive HIV-1 status
 - with previous hypersensitivity reaction to cabotegravir
 - receiving carbamazepine, oxcarbazepine, phenobarbital, phenytoin, rifampin, and rifapentine

Please see additional Important Safety Information continued throughout and full [Prescribing Information](#), including [Boxed Warning](#), for APRETUDE (cabotegravir).

FINDING MY HOME & *THE COURAGE TO BE ME*

—
Ruben





Ruben radiates resilience and positivity. Behind his smile is a thoughtful, gentle person who loves creativity and self-expression. Ruben and his doctor have shaped his approach to HIV protection, and APRETUDE is an important part of that.

Hi, Ruben. Thanks for joining us today. Please tell us about who you are, where you come from, and what you love to do.

Hello! I'm happy to be here and look forward to talking more about my experience. I am Latino, born in Venezuela and raised in Honduras, but today I live in New York City. I love the LGBTQIA+ community in the city. I listen to a lot of music and love to go dancing, and I'm really interested in art and fashion. It's a huge part of my life.

Let's talk about arriving in the US and eventually making your way to New York. What was the significance of that experience for you?

When I emigrated from Honduras to Miami, I started being able to accept myself as a gay man. I knew I would be safer in a more welcoming environment. Then, I was told my brother passed away in a car accident back in Honduras. That was an extremely difficult time, but since then, I have moved to New York City and built a life here that I love. I get the most out of living in New York—I love going to museums, seeing art and fashion in the streets, and I've created a community for myself here filled with other LGBTQIA+ people.

Would you say getting more comfortable with your sexual identity changed your approach to your sexual health?

During the period of depression following losing my brother, I felt alone, and my only interactions with people were through dating or "hook-up" apps. I had condomless sex and was constantly worrying about whether I was HIV-positive and how my family would react if I had to tell them I was. By the third time I needed an HIV test, I received counseling from an LGBTQIA+ inclusive sexual health center. I will always remember how calm and safe that place felt. The counselor told me about my options for HIV prevention, including PrEP, and it was an important introduction to eventually getting on APRETUDE.

How did you go from there to starting APRETUDE?

One day my workspace announced they would be working with the public hospital to make APRETUDE more accessible within vulnerable communities. Injectable PrEP is accessible? I thought, I've got to talk to my doctor about trying it! I ended up switching providers to an LGBTQIA+ affirming clinic at the public hospital, specifically so I could get APRETUDE.

IMPORTANT SAFETY INFORMATION (CONT'D)

WARNINGS AND PRECAUTIONS

Comprehensive Management to Reduce the Risk of HIV-1 Infection:

- Use APRETUDE as part of a comprehensive prevention strategy, including adherence to the administration schedule and safer sex practices, including condoms, to reduce the risk of sexually transmitted infections (STIs). APRETUDE is not always effective in preventing HIV-1 acquisition. Risk for HIV-1 acquisition includes, but is not limited to, condomless sex, past or current STIs, self-identified HIV risk, having sexual partners of unknown HIV-1 viremic status, or sexual activity in a high prevalence area or network. Inform, counsel, and support individuals on the use of other prevention measures (e.g., consistent and correct condom use; knowledge of partner[s] HIV-1 status, including viral suppression status; regular testing for STIs)

- Use APRETUDE only in individuals confirmed to be HIV-1 negative. HIV-1 resistance substitutions may emerge in individuals with undiagnosed HIV-1 infection who are taking only APRETUDE, because APRETUDE alone does not constitute a complete regimen for HIV-1 treatment. Prior to initiating APRETUDE, ask seronegative individuals about recent (in past month) potential exposure events and evaluate for current or recent signs or symptoms consistent with acute HIV-1 infection (e.g., fever, fatigue, myalgia, skin rash). If recent (<1 month) exposures to HIV-1 are suspected or clinical symptoms consistent with acute HIV-1 infection are present, use a test approved or cleared by the FDA as an aid in the diagnosis of acute HIV-1 infection

Your time on APRETUDE started with a new healthcare provider. How has your relationship with them evolved since the beginning?

I have a whole new provider and care team than before I started APRETUDE. Sometimes you need to make a change for what you feel is best for your life. I have built trust with my new doctor, and I can communicate anything I need. I trust that my doctor wants the best for me. I don't feel shame in sharing anything with him. With his guidance and my full toolbox of preventative steps, I can take action to protect my sexual health. I took in his reactions to stories I shared. His responses were professional, and I felt that we were on the same page. He understood a lot of things that I was saying, when I know not every doctor would. He understood I was looking for an injectable PrEP for HIV protection, and he was so knowledgeable about APRETUDE. He really listened to what I said.

Having a healthcare provider who listens to you is essential. How did you navigate conversations about your PrEP options?

I routinely talk to my doctor about all of my PrEP options, and we confirm that APRETUDE is still

the right fit for me. With APRETUDE, I feel good knowing I'm helping to protect myself from HIV, and with other preventative tools, helping to protect myself from other STIs. That's important to me, to feel confident in my body like I feel confident in my HIV prevention. I get tested before every injection to confirm my HIV-negative status, and I appreciate that I don't have to take extra steps to cover up the injection site, because the shot is given in the muscle of my butt.

Share one of your hopes for the future of HIV prevention with APRETUDE.

I hope that more people can work with a healthcare provider who listens to them and get the information they need. For me, until I found the provider who helped me get APRETUDE, I did not have the kind of relationship with my doctor where I felt I knew all the options that existed for me. And since then, I've seen my provider more and had more opportunities to take steps to be proactive about my health. I was so excited when I found out I could get APRETUDE. I think the most important thing is for people to know what's out there, and know that a doctor you trust is your most important partner for doing that.



IMPORTANT SAFETY INFORMATION (CONT'D)

WARNINGS AND PRECAUTIONS (CONT'D)

Comprehensive Management to Reduce the Risk of HIV-1 Infection: (cont'd)

- When using APRETUDE, HIV-1 testing should be repeated prior to each injection and upon diagnosis of any other STIs
- Additional HIV testing to determine HIV status is needed if an HIV-1 test indicates possible HIV-1 infection or if symptoms consistent with acute HIV-1 infection develop following an exposure event. If HIV-1 infection is confirmed, then transition the individual to a complete HIV-1 treatment
- Counsel individuals without HIV-1 to strictly adhere to the recommended dosing and testing schedule for APRETUDE

Potential Risk of Resistance with APRETUDE:

- There is a potential risk of developing resistance to APRETUDE if an individual acquires HIV-1 either before, while taking, or following discontinuation of APRETUDE. To minimize this risk, it is essential to clinically reassess individuals for risk of HIV-1 acquisition and to test before each injection to confirm HIV-1-negative status. Individuals who are confirmed to have HIV-1 infection must transition to a complete HIV-1 treatment. If individuals at continuing risk of HIV-1 acquisition discontinue APRETUDE, alternative forms of PrEP should be considered and initiated within 2 months of the final injection of APRETUDE

Please see additional Important Safety Information continued throughout and full [Prescribing Information](#), including [Boxed Warning](#), for APRETUDE (cabotegravir).



TELLING
my
story,
FOR
my
community

Leo

Leo has experience with HIV prevention from more than one perspective. He has remained strong through a series of challenges, and never lost sight of the need to look out for himself and his community.

Thank you for joining us today, Leo. Can you start by telling us a bit about yourself?

I'm currently working full time as an infectious disease care coordinator, and I'm also working on my bachelor's and master's in public health. My ultimate goal is to become a physician assistant. I have a unique personal style. Halloween was a few months ago, but I have bats decorating my house year-round! I spend most of my time at home with my cat and my dog, but I also have a strong support system in my friends.

What in your story has impacted your HIV awareness?

Part of the story of my HIV awareness is my own personal history. During one time in my life, I worried I might become HIV-positive because I wasn't always careful with drugs and with sex. It was scary, but at the time I was not ready to take control of my health.

What in your story motivated you to consider PrEP to help prevent HIV?

I know PrEP is specifically to prevent someone from getting HIV through sex. It was while I was working as a sex worker that I felt that PrEP would be a good idea for me. I tried the oral PrEP that was available at the time, but it did not work well for me with my lifestyle at the time. Since then, I came out as trans and embraced my sexuality, which includes a polyamorous approach. As I navigated my transition, I also started working as a PrEP navigator, which introduced me to APRETUDE. When I heard about it, I knew I needed to talk to my doctor to find out if APRETUDE could be an option for me.

What did getting on APRETUDE look like for you?

Once I found a provider who respected my gender identity, sexuality, and history, it didn't take long for me to start APRETUDE. I discussed it with my doctor and we determined together that APRETUDE was a good fit for me. Accessing APRETUDE wasn't the hard part—for people like me, the real wait was for care that felt safe. I chose to wait for an appointment at an LGBTQIA+ clinic, and when I got my foot in the door there, I knew I had found the right place.

With several PrEP options available, why do you continue taking APRETUDE?

I continue with APRETUDE because the dosing schedule fits well with my life. I already administer my testosterone injections in my stomach. I appreciate that APRETUDE is injected at a different, discreet site (gluteal). I also value the regular, bimonthly check-ins with my provider. Honestly, I wouldn't take myself to the doctor otherwise. Those visits keep me on track with my STI and HIV testing, which is really important to me. Even with PrEP, it's still vital to know your status. I've also learned how important it is to have open conversations with your healthcare provider about all medications—prescription, over-the-counter, or otherwise—especially for people in recovery. I feel APRETUDE is helping protect me from HIV, and I feel informed and supported by my provider.

Share one of your hopes for the future of HIV prevention with a PrEP option like APRETUDE.

I look forward to seeing APRETUDE continue to be normalized in the wider LGBTQIA+ community. There is a lot of education to be done about PrEP including in my community. When people know that APRETUDE is an option, they can recognize if it's something they should discuss with their doctor.

IMPORTANT SAFETY INFORMATION (CONT'D)

WARNINGS AND PRECAUTIONS (CONT'D)

Long-Acting Properties and Potential Associated Risks with APRETUDE:

- Residual concentrations of cabotegravir may remain in the systemic circulation of individuals for prolonged periods (up to 12 months or longer). Take the prolonged-release characteristics of cabotegravir into consideration and carefully select individuals who agree to the required every-2-month injection dosing schedule because non-adherence or missed doses could lead to HIV-1 acquisition and development of resistance

Hypersensitivity Reactions:

- Serious or severe hypersensitivity reactions have been reported with APRETUDE, including Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN)

- Discontinue APRETUDE immediately if signs or symptoms of hypersensitivity reactions develop. Clinical status, including liver transaminases, should be monitored and appropriate therapy initiated

Hepatotoxicity:

- Hepatotoxicity has been reported in a limited number of individuals receiving cabotegravir with or without known pre-existing hepatic disease or identifiable risk factors
- Clinical and laboratory monitoring should be considered and APRETUDE should be discontinued if hepatotoxicity is suspected and individuals managed as clinically indicated

Depressive Disorders:

- Depressive disorders (including depression, depressed mood, major depression, persistent depressive disorder, suicidal ideation or attempt) have been reported with APRETUDE

Please see additional Important Safety Information continued throughout and full Prescribing Information, including Boxed Warning, for APRETUDE (cabotegravir).

*“I have a story to tell
& I know if it reaches
the right people,
IT CAN MAKE
A DIFFERENCE*

”

- Zach

Here's to moving forward

From all of us at ViiV, thank you for the work you do on the behalf of the communities we serve. For 4 years, you have helped patients access APRETUDE, the first long-acting PrEP option—and we look forward to continuing to partner together to help prevent HIV.



Thank you:

**APRETUDE Ambassadors
Feature Photographer**

Leo, Zach, Shae, Ruben (Compensated by ViiV Healthcare)
Malike Sidibe (unless otherwise noted)

IMPORTANT SAFETY INFORMATION (CONT'D)

WARNINGS AND PRECAUTIONS (CONT'D)

Risk of Reduced Drug Concentration of APRETUDE Due to Drug Interactions:

- The concomitant use of APRETUDE and other drugs may result in reduced drug concentration of APRETUDE
- Refer to the full Prescribing Information for steps to prevent or manage these possible and known significant drug interactions, including dosing recommendations. Consider the potential for drug interactions prior to and during use of, and after discontinuation of APRETUDE; review concomitant medications during use of APRETUDE

ADVERSE REACTIONS

The most common adverse reactions (incidence $\geq 1\%$, all grades) with APRETUDE were injection site reactions, diarrhea, headache, pyrexia, fatigue, sleep disorders, nausea, dizziness, flatulence, abdominal pain, vomiting, myalgia, rash, decreased appetite, somnolence, back pain, and upper respiratory tract infection.

DRUG INTERACTIONS

- Refer to the full Prescribing Information for important drug interactions with APRETUDE
- Drugs that induce UGT1A1 may significantly decrease the plasma concentrations of cabotegravir

References: 1. A timeline of HIV and AIDS. HIV.gov. Accessed June 27, 2025. <http://www.hiv.gov/hiv-basics/overview/history/hiv-and-aids-timeline> 2. The 40 year fight against HIV. Behind the science magazine. GSK. <https://www.gsk.com/en-gb/behind-the-science-magazine/the-40-year-fight-against-hiv/> 3. American Chemical Society. Discovery of highly active antiretroviral therapy for HIV. Accessed July 18, 2025. <https://www.acs.org/education/whatischemistry/landmarks/highly-active-antiretroviral-therapy-hiv.html> 4. ViiV Healthcare. Our history and mission. Accessed June 27, 2025. <https://viiVhealthcare.com/en-us/about-viiV/history-and-mission>

Please see additional Important Safety Information continued throughout and full [Prescribing Information](#), including Boxed Warning, for APRETUDE (cabotegravir).



Please see Important Safety Information throughout and full [Prescribing Information](#), including Boxed Warning, for APRETUDE.



For US Healthcare Professionals only.
Trademarks are property of their respective owners.
©2026 ViiV Healthcare or licensor.
PMUS-CBTLBND250071 January 2026 Produced in USA.

 **Apretude**
cabotegravir 200 mg/mL
extended-release injectable suspension